SCHEMBL973168

SCHEMBL973168

c1ccc(-c2nc(-c3ccccn3)cc(-c3c4ccccc4cc4ccccc34)n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 7/20 0.49
CCR1 P32246 3/20 0.47
CCR5 P51681 3/20 0.47
CCR8 P51685 3/20 0.47
SMN1; SMN2 Q16637 4/20 0.44
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
LMNA P02545 4/20 0.42
KDM4E B2RXH2 4/20 0.42
METAP1 P53582 3/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
BLM P54132 1/20 0.42
HIF1A Q16665 1/20 0.42
DOHH Q9BU89 1/20 0.42
P4HTM Q9NXG6 1/20 0.42
MAPK1 P28482 2/20 0.42
HSP90AA1 P07900 2/20 0.42
HPGD P15428 2/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12579263 0.88 DHODH (0.48) ADORA3CCR1CCR5CCR8SMN1; SMN2
SCHEMBL10051240 0.87 DHODH (0.47) ADORA3CCR1CCR5CCR8SMN1; SMN2
SCHEMBL971862 0.85 CCR1 (0.45) ADORA3CCR1CCR5CCR8SMN1; SMN2
SCHEMBL28190882 0.85 KDM4E (0.58) CCR1CCR5CCR8SMN1; SMN2NPC1
SCHEMBL971571 0.85 MAPK1 (0.48) ADORA3CCR1CCR5CCR8SMN1; SMN2
SCHEMBL971520 0.85 SMN1; SMN2 (0.48) ADORA3CCR1CCR5CCR8SMN1; SMN2
SCHEMBL971280 0.84 MEN1 (0.55) ADORA3SMN1; SMN2LMNAKDM4EMAPK1
SCHEMBL6551807 0.83 KDM4E (0.54) ADORA3CCR1CCR5CCR8SMN1; SMN2
SCHEMBL22766675 0.82 KDM4E (0.43) ADORA3CCR1CCR5CCR8SMN1; SMN2
SCHEMBL18698104 0.82 MEN1 (0.56) CCR1CCR5CCR8SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7867629-B2 Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same IDEMITSU KOSAN CO., LTD. (JP) 2011-01-11 US disclosed
US-20060154105-A1 Nitrogenous heterocyclic derivative and organic elecrtroluminescent element employing the same IDEMITSU KOSAN CO., LTD. (JP) 2006-07-13 US disclosed
EP-1582516-A1 NITROGENOUS HETEROCYCLIC DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154105-A1 Nitrogenous heterocyclic derivative and organic elecrtroluminescent element employing the same L1CAM, NOTCH1, NUDC ADORA3 3036/4885CCR1 4435/4885CCR5 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.